DK1653950T3 - Nitrooxyderivater af Losartan, Valsatan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-receptorblokkere til behandling af cardiovaskulære sygdomme - Google Patents

Nitrooxyderivater af Losartan, Valsatan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-receptorblokkere til behandling af cardiovaskulære sygdomme

Info

Publication number
DK1653950T3
DK1653950T3 DK04766269T DK04766269T DK1653950T3 DK 1653950 T3 DK1653950 T3 DK 1653950T3 DK 04766269 T DK04766269 T DK 04766269T DK 04766269 T DK04766269 T DK 04766269T DK 1653950 T3 DK1653950 T3 DK 1653950T3
Authority
DK
Denmark
Prior art keywords
valsatan
olmesartan
eprosartan
telmisartan
candesartan
Prior art date
Application number
DK04766269T
Other languages
Danish (da)
English (en)
Inventor
Nicoletta Almirante
Soldato Piero Del
Ennio Ongini
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Application granted granted Critical
Publication of DK1653950T3 publication Critical patent/DK1653950T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK04766269T 2003-07-31 2004-07-20 Nitrooxyderivater af Losartan, Valsatan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-receptorblokkere til behandling af cardiovaskulære sygdomme DK1653950T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102379 2003-07-31
PCT/EP2004/051550 WO2005011646A2 (en) 2003-07-31 2004-07-20 Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
DK1653950T3 true DK1653950T3 (da) 2008-05-26

Family

ID=34112476

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04766269T DK1653950T3 (da) 2003-07-31 2004-07-20 Nitrooxyderivater af Losartan, Valsatan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-receptorblokkere til behandling af cardiovaskulære sygdomme

Country Status (30)

Country Link
US (1) US20060276523A1 (de)
EP (1) EP1653950B1 (de)
JP (1) JP2007500684A (de)
KR (1) KR20060056352A (de)
CN (1) CN100496490C (de)
AR (1) AR045145A1 (de)
AT (1) ATE383155T1 (de)
AU (1) AU2004260830B2 (de)
BR (1) BRPI0413028A (de)
CA (1) CA2534451A1 (de)
CY (1) CY1110447T1 (de)
DE (1) DE602004011230T2 (de)
DK (1) DK1653950T3 (de)
EC (1) ECSP066334A (de)
ES (1) ES2299861T3 (de)
HK (1) HK1095093A1 (de)
HR (1) HRP20060084A2 (de)
IL (1) IL172703A0 (de)
IS (1) IS2534B (de)
MA (1) MA27987A1 (de)
MX (1) MXPA06001263A (de)
NO (1) NO20060900L (de)
NZ (1) NZ544463A (de)
PL (2) PL379420A1 (de)
PT (1) PT1653950E (de)
RU (1) RU2374240C2 (de)
SI (1) SI1653950T1 (de)
UA (1) UA87983C2 (de)
WO (1) WO2005011646A2 (de)
ZA (1) ZA200600856B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005263655A1 (en) * 2004-07-20 2006-01-26 Nicox S.A. Process for preparing nitrooxy esters, nitrooxy thioesters, nitrooxy carbonates and nitrooxy thiocarbonates, intermediates useful in said process and preparation thereof
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑-5-羧酸类衍生物、制备方法及其应用
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
US8362066B2 (en) 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
EP2103610B1 (de) * 2006-12-06 2011-09-21 Shanghai Allist Pharmaceutical., Inc. Salze von imidazol-5-carbonsäure-derivaten, herstellungsverfahren und verwendung davon
JP2010513273A (ja) * 2006-12-13 2010-04-30 メルク アンド カンパニー インク. アンジオテンシンii受容体拮抗薬
TW200831079A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
CN101214242A (zh) * 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
EP1980559A1 (de) * 2007-04-10 2008-10-15 CTG Pharma S.r.l. Kardiovaskuläre Wirkstoffe
CN101317842A (zh) 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) * 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
AR069340A1 (es) * 2007-11-26 2010-01-13 Merck & Co Inc Antagonistas del receptor de angiotensina ii
EP2534958A1 (de) 2007-12-14 2012-12-19 AeroDesigns, Inc Abgabe von Aerosol-sprühbaren Nahrungsmittelprodukten
EP2244575B1 (de) * 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin-ii-rezeptorantagonisten
CA2711461A1 (en) * 2008-02-08 2009-08-13 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
EP2250164A2 (de) * 2008-02-26 2010-11-17 Nicox S.A. Angiotensin-ii-rezeptor-blockerderivate
CA2712689A1 (en) * 2008-02-26 2009-09-03 Nicoletta Almirante Angiotensin ii receptor antagonists
CA2723725A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
CA2724919A1 (en) * 2008-06-09 2009-12-17 Nicox S.A. Angiotensin ii receptor antagonists
AR073259A1 (es) * 2008-07-29 2010-10-28 Merck & Co Inc Derivados de furosemida utiles como diureticos
WO2010015447A1 (en) * 2008-08-08 2010-02-11 Nicox S.A. Angiotensin ii receptor antagonists
EP2194048A1 (de) 2008-12-02 2010-06-09 Dirk Sartor Nitratester zur Behandlung von vaskularen und metabolischen Krankheiten
AR074425A1 (es) 2008-12-05 2011-01-19 Merck Sharp & Dohme Derivados de nitrooxi como antagonistas del receptor de angiotensina ii.
WO2010085014A1 (en) 2009-01-23 2010-07-29 Hanmi Pharm. Co., Ltd. Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
CN103080095A (zh) 2010-04-19 2013-05-01 心脏林克斯股份公司 用于治疗血管和代谢疾病的携带氮氧化物给体的缬沙坦衍生物
WO2011132171A1 (en) * 2010-04-23 2011-10-27 Piramal Life Sciences Limited Nitric oxide releasing prodrugs of therapeutic agents
WO2011160974A2 (en) 2010-06-21 2011-12-29 Nicox S.A. Statin derivatives
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
CA2897571C (en) 2013-01-21 2018-12-18 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group
CN103275074B (zh) * 2013-06-21 2016-08-10 黄冈鲁班药业股份有限公司 一种奥美沙坦衍生物及其制备方法
CN105820125B (zh) * 2015-01-09 2018-12-07 北京中医药大学 一种用于治疗高血压的化合物及其制备方法和用途
JP2018526448A (ja) 2015-09-07 2018-09-13 浙江華海薬業股▲フン▼有限公司 一酸化窒素を放出可能なプロドラッグ分子
CN106800537B (zh) * 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN108892624B (zh) * 2018-06-20 2020-12-15 重庆威鹏药业有限公司 沙库巴曲硝基氧衍生物及其制备方法和应用
CN114105881B (zh) * 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10075018I2 (de) * 1989-06-14 2001-08-09 Smithkline Beecham Corp Imidazoalkensäure.
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
CA2420055C (en) * 2000-08-25 2010-06-01 Takeda Chemical Industries, Ltd. Fibrinogen-lowering agent
ITMI20011744A1 (it) * 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie

Also Published As

Publication number Publication date
US20060276523A1 (en) 2006-12-07
BRPI0413028A (pt) 2006-10-03
HRP20060084A2 (hr) 2006-04-30
IS8332A (is) 2006-02-27
IL172703A0 (en) 2006-04-10
NZ544463A (en) 2009-10-30
HK1095093A1 (en) 2007-04-27
IS2534B (is) 2009-08-15
ZA200600856B (en) 2007-05-30
SI1653950T1 (sl) 2008-06-30
ES2299861T3 (es) 2008-06-01
ATE383155T1 (de) 2008-01-15
DE602004011230D1 (de) 2008-02-21
AR045145A1 (es) 2005-10-19
PT1653950E (pt) 2008-04-11
AU2004260830A1 (en) 2005-02-10
RU2374240C2 (ru) 2009-11-27
AU2004260830B2 (en) 2010-04-29
CY1110447T1 (el) 2015-04-29
CN1832742A (zh) 2006-09-13
RU2006105804A (ru) 2007-09-20
UA87983C2 (ru) 2009-09-10
PL379420A1 (pl) 2006-09-04
EP1653950A2 (de) 2006-05-10
CA2534451A1 (en) 2005-02-10
MA27987A1 (fr) 2006-07-03
CN100496490C (zh) 2009-06-10
JP2007500684A (ja) 2007-01-18
WO2005011646A3 (en) 2005-04-21
WO2005011646A2 (en) 2005-02-10
EP1653950B1 (de) 2008-01-09
KR20060056352A (ko) 2006-05-24
ECSP066334A (es) 2006-07-28
NO20060900L (no) 2006-02-24
MXPA06001263A (es) 2006-04-11
DE602004011230T2 (de) 2009-01-02
PL1653950T3 (pl) 2008-08-29

Similar Documents

Publication Publication Date Title
DK1653950T3 (da) Nitrooxyderivater af Losartan, Valsatan, Candesartan, Telmisartan, Eprosartan og Olmesartan som angiotensin II-receptorblokkere til behandling af cardiovaskulære sygdomme
NO2012017I2 (no) Azilsartan medoxomil og farmasøytisk akseptabelt salt derav, innbefattende kaliumsalt
NL2000371A1 (nl) Chromaan gesubstitueerde benzimidazoolderivaten.
NO20053245D0 (no) Tabletter med modifisert frigjoring av bupropionhydroklorid.
TWI351075B (en) Semiconductor device, embedded memory, and method of fabricating the same
IL181550A0 (en) Purification of olmesartan medoxomil
DE602005018493D1 (de) Wärmegeregelte, fluidische selbstmontage
DE602005007633D1 (de) Wärmegeregelte, fluidische selbstmontage
DE502005009133D1 (de) Hydraulik-dehnspannfutter
DE602006019852D1 (de) Verriegelungsspannfutter
WO2009058950A3 (en) Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
DK1626964T3 (da) Nye benzimidazolderivater
EP2172415A4 (de) Silizium-struktur, methode zu deren herstellung und sensorchip
IL176630A0 (en) Benzimidazole derivatives
SE0600781L (sv) Halvledaranordning av kiselkarbid
BRPI0913613A2 (pt) composto, medicamento, e, agente antagonizante do receptor sensível a cálcio
IL176140A0 (en) Candesartan cilexetil polymorphs
ATE492546T1 (de) 6-phenyl-1h-imidazoä4,5-cü-pyridin-4- carbonitrilderivate als cathepsin-hemmer
ATE463496T1 (de) 6-phenyl-1h-imidazoä4, 5-cüpyridin-4-carbonitril- derivate als cathepsin-k- und -s-hemmer
DE602006000612D1 (de) Beidseitig tragbare Orthese
DK1906972T3 (da) LPA2-receptoragonist til behandling af diarré
DE602006017413D1 (de) Siliciumcarbid-halbleiteranordnung
NL1031384A1 (nl) Gesubstitueerde aryl-1,4-pyrazinederivaten.
EP2348843A4 (de) Protonengekoppelter selektiver folattransporter und folatrezeptor, garftase-hemmerverbindungen und anwendungsverfahren dafür
CL2004000379A1 (es) Uso de una combinacion farmaceutica de lercanidipina con un bloqueador de los receptores de angiotensina ii, seleccionado de olmesartan, irbesartan, valsartan, telmisartan y losartan, para tratar la hipertension.